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Abstract

Background: Most early childhood immunizations require 3-4 doses to achieve optimal disease protection.
Failure to complete multi-dose vaccine series is an important driver of undervaccination. Our objective was to
evaluate factors associated with starting but not completing all multi-dose series in the combined 7-vaccine series.
Methods: Using 2019 National Immunization Survey-Child data, U.S. children ages 19-35 months with provider
verified vaccination data were classified in one of three vaccination patterns: (1) completed the combined 7vaccine series, (2) missing ≥1 vaccine series (i.e., selective vaccination), or (3) all series initiated, but did not
complete all multi-dose series (i.e., missing ≥1 dose(s)). Associations between sociodemographic factors and
starting but failing to complete all multi-dose vaccine series were evaluated using multivariable logistic regression
(pattern 3 vs. 1 and 2). Analyses accounted for the stratified survey design and complex survey weighting.
Results: Among N=16,365 children ages 19-35 months, n=12,390 (72.7%) completed the combined 7-vaccine
series, n=1,511 (9.9%) were classified as missing ≥1 vaccine series, and n=2,464 (17.3%) had initiated all vaccine
series, but did not complete all multi-dose series. Vaccination coverage for multi-dose series was lower compared
to single dose series. 8.2% of all U.S. children needed only one additional dose to complete the combined 7vaccine series. After adjusting for sociodemographic differences, the strongest associations with starting but not
completing all multi-dose vaccine series were geographic mobility (aOR: 1.66, 95% confidence interval [CI]:
1.24-2.23), number of children <18 years of age in the household (two to three: aOR: 1.36, 95% CI: 1.07-1.73;
four or more: aOR: 1.93, 95% CI: 1.38-2.70), and lack of insurance coverage (aOR: 3.21, 95% CI: 1.56-6.62), as
compared to children who completed the combined 7-vaccine series.
Conclusions: Risk factors for starting but failing to complete multi-dose vaccine series included lower
socioeconomic status, moving across state lines since birth, having multiple children in the household, and being
uninsured. Increased focus on strategies to encourage multi-dose series completion is needed to decrease rates of
undervaccination and eliminate structural or other barriers to vaccination.
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Introduction
Vaccines are among the greatest public health success stories of the 20th century.1-4 As a safe and costeffective strategy for promoting pediatric health and preventing illness, approximately 20 million cases of
infectious diseases, 40,000 premature deaths, and an estimated net savings of $70 billion in direct and societal
costs in the U.S. annually have been attributed to the delivery of early childhood immunizations.5-11 During the
first two years of a child’s life, the U.S. Advisory Committee on Immunization Practices (ACIP) recommends 10
vaccine series, each consisting of 1-4 vaccine doses, to protect against 14 diseases. However, previous studies
have shown between 50% and 75% of U.S. children are undervaccinated at some point in the first two years of
life, with the greatest immunization disparities observed by race and ethnicity, poverty status, and health insurance
status.12-17 Failure to complete all doses of ACIP-recommended vaccine series is an important public health
problem, because undervaccination increases vulnerability to preventable outbreaks of infectious diseases and
has the potential to exacerbate health inequities among pediatric populations. Infants at greatest risk for severe
sequalae from vaccine preventable diseases (e.g., encephalopathy, apnea, pneumonia, seizures, urinary
incontinence, in some cases death) and too young to be vaccinated rely on protection from high levels of
community vaccination. Most vaccine series recommended to children ages 0-24 months are multi-dose series
that require three or four doses to achieve optimal disease protection, including diphtheria, tetanus, and acellular
pertussis (DTaP), pneumococcal conjugate vaccine (PCV), Haemophilus influenzae type b (Hib), poliovirus
(IPV), and hepatitis B (HepB) vaccine series (Table S1). Initiating but not completing all doses of vaccine series
does not optimally protect a child at the individual level, and series non-completion threatens herd immunity at
the population level by permitting a gap for highly infectious pathogens to exploit and spread within and across
communities. High levels of vaccination coverage are needed to curb outbreaks and protect the youngest and most
vulnerable of children.
There has been a resurgence of vaccine preventable diseases (VPDs) in the U.S. in recent years.8, 18-30
Because of this, deviations from the ACIP-recommended schedule, including not completing multi-dose series,
delayed vaccine receipt and not receiving specific vaccine series, are of utmost concern to combat these increases.
Recent outbreaks of measles, pertussis, and invasive pneumococcal disease have caused avoidable suffering, and
the primary prevention strategy is vaccination. Measles as well as pertussis both have an estimated reproductive
number (R0) of 15-17, and require high levels of vaccination coverage (estimated up to 94%) to prevent disease
spread.31-33 One out of every four children infected with measles will be hospitalized, and for every 1,000 cases,
on average, one child will die.34 For pertussis, approximately 50% of infants will be hospitalized, and studies have
shown missing only the final dose of the four dose DTaP series is associated with a three times greater risk of
infection.13, 35-40 Invasive pneumococcal disease is a leading cause of meningitis, sepsis, and mortality among
neonates and infants worldwide.41 The complex molecular epidemiology of pneumococcus serotypes and growing
antimicrobial resistance underpin the importance of complete vaccination.42-44 Failure to complete multi-dose
vaccine series on-time, specifically four dose DTaP and PCV vaccine series protecting against pertussis and
invasive pneumococcal disease, respectively, increases VPD risk, and lower coverage for multi-dose series is an
important driver of low combined 7-vaccine series completion rates.19, 40, 45, 46
The combined 7-vaccine series is a standard measure used to evaluate coverage and requires children to
be up-to-date (UTD) on seven individual vaccine series: four doses of DTaP, four doses of PCV, three or four
doses of Hib depending on brand, three doses of IPV, three doses of HepB, one dose of measles, mumps, rubella
(MMR), and one dose of varicella (VAR). To achieve the Healthy People 2020 goals of 90% coverage for each
vaccine series and 80% coverage for the combined 7-vaccine series, the final doses of multi-dose vaccine series
must be completed.47 Among U.S. children born 2017-2018, ≥90% coverage for HepB, IPV, MMR, and VAR
was achieved. However, vaccination coverage for multi-dose DTaP, PCV, Hib remained below target 90%
coverage for each series, resulting in suboptimal coverage overall for the combined 7-vaccine series at 70.5% by
age 24 months.17 Completing all multi-dose vaccine series is an evidence-based strategy to decrease risk of
pediatric morbidity and mortality, maximize protection to individuals and populations of young children, and
needed to respond to the observed resurgence of VPDs.35, 38, 48 Since 1994, the Centers for Disease Control and
Prevention (CDC) has been monitoring vaccination coverage by ages 19-35 months through the annual National
Immunization Survey (NIS) to measure progress toward the Healthy People vaccination goals.23, 48, 49
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There are multiple reasons why U.S. vaccination rates are lower than public health goals.17, 23 One
explanation is parental vaccine hesitancy and refusal. While only about 1.0-1.4% of children receive no
immunizations by age 24 months, it has been estimated that between 7.6% and 22.7% of U.S. parents choose to
selectively vaccinate their children against only certain diseases (i.e., initiating some vaccine series and not
others).12-14, 17, 50-53 One additional explanation for why the U.S. fails to meet vaccination goals is children starting
but failing to complete multi-dose vaccine series. Starting but failing to complete multi-dose vaccine series could
occur due to challenges accessing immunization providers, fragmentation of care, adverse reactions to prior doses,
parental feelings toward the urgency or timeliness of vaccination changing after initiating a series, or decreased
perceived individual level risk after partial vaccination.
Previous studies describing barriers to and facilitators of early childhood immunizations have focused on
parental vaccine hesitancy, with less of an emphasis on structural or other barriers. Starting but not completing
all multi-dose vaccine series suggest a child faced barriers that were not vaccine hesitancy, and while structural
barriers to preventive health care services are broad, distinguishing between parental hesitancy and other access
barriers can allow for more efficient allocation of resources toward improving vaccine uptake. To fill this evidence
gap and inform initiatives to better promote pediatric health by improving immunization equity, the objective of
this study was to describe children who started, but did not complete, all multi-dose vaccine series and to evaluate
factors associated with failure to complete all doses of multi-dose vaccine series.
Methods
Data source
NIS-Child data collected in 2019 were analyzed in this study. NIS-Child is a nationally representative
telephone survey conducted annually by the CDC; survey methodology has been previously described in detail
in the literature.12, 14, 37-39 Using two phases of sampling, a random-digit-dialing method is used to contact
caregivers of age-eligible children, followed by a medical record review questionnaire mailed to providers to
verify a child’s immunization history.49 The study population included U.S. non-institutionalized children ages
19-35 months surveyed in 2019 with provider verified data.
Outcome measures and definitions
Vaccination coverage evaluated in this cross-sectional study and all subsequent analyses included all
vaccines in the combined 7-vaccine series: DTaP, PCV, Hib, IPV, HepB, MMR, and VAR. Children in the study
population were classified in one of three vaccination patterns: (1) completed the combined 7-vaccine series, (2)
missing ≥1 vaccine series (i.e., selective vaccination), or (3) all series initiated, but did not complete all multidose series (i.e., missing ≥1 dose(s)). The main outcome of interest was the third pattern: children who received
at least one dose of each of the seven vaccine series, but were missing ≥1 dose(s) of at least one multi-dose series
(DTaP, PCV, Hib, IPV, or HepB) at the time of the NIS household interview (age 19-35 months). Among children
undervaccinated in patterns 2 and 3, missing vaccine series and doses were described. The number and percentage
of children in each vaccination pattern of the 3-level outcome were reported. While a child could be missing doses
in one or more multi-dose vaccine series (pattern 3) or be missing multiple vaccine series (pattern 2), the 3-level
outcome was mutually exclusive as children in pattern 3, by definition, must have initiated all seven individual
vaccine series.
Statistical Analyses
Demographic and other characteristics of the study population were reported. Bivariate associations
between sociodemographic factors and vaccination pattern were measured and statistical significance was
evaluated using Rao-Scott chi-square tests. For undervaccinated children, UTD coverage by vaccine type, by
vaccine dose, and the timing of first dose administration were described. Among children undervaccinated in
5

pattern 2, missing ≥1 vaccine series, and pattern 3, all series initiated, but did not complete all multi-dose series,
the number of remaining doses needed to complete the combined 7-vaccine series was reported.
Multivariable logistic regression was used to identify the sociodemographic factors associated with
vaccination pattern. Exposures of interest were measures suggestive of fragmented care, including geographic
mobility, number of vaccine providers, and breaks in insurance coverage. In the primary analysis, a sub-cohort of
children who had either started but failed to complete multi-dose vaccine series (pattern 3) or completed the
combined 7-vaccine series (pattern 1) were compared. In the secondary analysis, a sub-cohort of undervaccinated
children in pattern 3 were compared to pattern 2, missing ≥1 vaccine series. All sociodemographic characteristics
were considered for inclusion in these models. Child’s birth order and insurance coverage were dropped from the
final models due to multicollinearity with number of children <18 years of age in the household and breaks in
insurance coverage and high variance inflation factors. Unadjusted and adjusted estimates were reported.
Complex survey design was accounted for in all analyses using the survey procedures adjusted for sample
weighting, clustering, and strata. All percentages reported were weighted to reflect population-based estimates.
All analyses were conducted using SAS statistical software version 9.4 (Cary, NC).
Results
Vaccine series completion and vaccination patterns
Among N=16,365 U.S. children ages 19-35 months, n=12,390 (72.7% of the study population) completed
the combined 7-vaccine series (pattern 1). For individual vaccine series, coverage exceeded 90% for four out of
seven series (IPV: 92.3%, MMR: 91.8%, HepB: 91.3%, and VAR: 90.9%); however, three multi-dose series
remained below target coverage (DTaP: 83.3%, PCV: 82.5% Hib: 81.6%; Table S2). Among children not UTD
for the combined 7-vaccine series, n=1,511 (9.9% of the study population) were classified as pattern (2) missing
≥1 vaccine series and n=2,464 (17.3% of the study population) were coded as pattern (3) all series initiated, but
did not complete all multi-dose series (Figure 1).
Of the three patterns, selective vaccination (pattern 2) was the least prevalent vaccination pattern.
Approximately 1.1% of the total study population received zero vaccines. Two vaccines recommended after a
child’s first birthday, VAR and MMR, were the most commonly missing series, with 8.8% of children not
initiating VAR and 8.2% missing MMR. The weighted percentage of children missing each of the five other series
ranged from 2.0-3.7% of the total population. Within the third level of the outcome, the main pattern of interest,
children were missing ≥1 dose(s) of Hib (14.8%), PCV (13.8%), and DTaP (13.4%) most frequently, followed by
HepB (6.6%) and IPV (4.1%; Figure 1).
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Figure 1. Classification structure of 3-level vaccination pattern outcome variable

Table 1. Characteristics of study population and bivariate associations between sociodemographic factors and vaccine pattern at the time of household
interview, U.S. children ages 19-35 months, NIS-Child 2019
Vaccination pattern

Sociodemographic factors

Total study
sample
N = 16,365

Completed the combined
7-vaccine series
n = 12,390 (72.7%)

Missing ≥ 1 vaccine
series
n = 1,511 (9.9%)

All series initiated, but did not
complete all multi-dose series
n = 2,464 (17.3%)

n
(column %)

n
(column %)

n
(column %)

n
(column %)

Child’s sex
Female
Male
Race and ethnicity
White alone, non-Hispanic
Black alone, non-Hispanic
All other races alone and multiple
races, non-Hispanic
Any race, Hispanic
Child’s age at time of survey
interview
19-23 months
24-29 months
30-35 months
Census region
Northeast
South
West
Midwest
Geographic mobility
Has moved across state lines since
birth
Has not moved across state lines
since birth
Vaccine provider facility type

p-value
(DF)a
0.524 (2)

7,776 (48.8%)
8,589 (51.2%)

5,904 (51.2%)
6,486 (48.8%)

722 (51.7%)
789 (48.3%)

1,150 (47.5%)
1,314 (52.5%)
0.002 (6)

9,803 (47.2%)
1,144 (12.7%)
2,107 (12.9%)

7,623 (49.2%)
794 (11.5%)
1,541 (13.0%)

853 (43.0%)
140 (14.0%)
224 (14.2%)

1,327 (40.8%)
210 (16.7%)
342 (11.8%)

3,311 (27.3%)

2,431 (26.2%)

294 (28.8%)

585 (30.7%)
0.008 (4)

5,068 (30.0%)
5,052 (33.6%)
6,245 (36.3%)

3,673 (28.2%)
3,878 (34.7%)
4,839 (37.1%)

526 (35.7%)
449 (32.5%)
536 (31.7%)

869 (34.4%)
725 (29.7%)
870 (35.9%)
0.1747 (6)

2,748 (15.8%)
6,563 (39.3%)
3,657 (24.1%)
3,397 (20.8%)

2156 (16.2%)
4,974 (39.3%)
2,656 (23.2%)
2,604 (21.4%)

236 (15.5%)
579 (35.3%)
404 (27.6%)
292 (21.7%)

356 (14.5%)
1,010 (41.5%)
597 (26.3%)
501 (17.7%)
<0.001 (2)

1,771 (10.7%)

1,129 (8.9%)

264 (14.6%)

378 (15.6%)

14,594 (89.3%)

11,261 (91.1%)

1,247 (85.4%)

2,086 (84.4%)
<0.001 (8)
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All private facilities
All public facilities
All hospital facilities
All military/other facilities
Mixed facility types
Number of vaccine providersb
One
Two
Three or more
Maternal education
<12 years
12 years
>12 years
College graduate
Child ever received WIC benefits
Yes
Not yesc
Child’s birth order
Firstborn
Not firstborn
Number of children <18 years of age
in the house
One
Two or three
Four or more
Home ownership
Home was owned or being bought
Home was rented
Other arrangement
Did not know or refused to answer
Poverty status
Above poverty, ≥$$75,000
Above poverty, ≤$75,000
Below poverty

8,736 (56.6%)
1,740 (12.4%)
2,796 (14.5%)
435 (3.2%)
2,371 (13.3%)

7,000 (59.7%)
1,193 (10.9%)
2,084 (13.6%)
312 (2.9%)
1,801 (12.9%)

523 (45.0%)
169 (15.6%)
318 (22.9%)
53 (4.1%)
161 (12.4%)

1,213 (49.5%)
378 (17.0%)
394 (13.9%)
70 (3.8%)
409 (15.7%)
<0.001 (4)b

13,290 (84.0%)
2,506 (13.5%)
282 (1.5%)

10,170 (84.0%)
1,999 (14.5%)
221 (1.5%)

1079 (82.4%)
136 (7.9%)
9 (0.3%)

2,041 (85.0%)
371 (12.8%)
52 (2.2%)

1,398 (14.2%)
2,552 (24.8%)
4,204 (22.0%)
8,211 (39.1%)

915 (12.0%)
1,774 (23.6%)
3,059 (21.7%)
6,642 (42.7%)

181 (20.1%)
294 (27.7%)
456 (25.8%)
580 (26.4%)

302 (20.2%)
484 (27.9%)
689 (20.9%)
989 (30.9%)

<0.001 (6)

<0.001 (2)
6,297 (48.9%)
10,068 (51.2%)

4,508 (46.1%)
7,882 (53.9%)

633 (54.5%)
878 (45.5%)

1,156 (57.0%)
1,308 (43.0%)
<0.001 (2)

6,327 (37.0%)
10,038 (63.0%)

5,042 (39.4%)
7,348 (60.6%)

485 (31.7%)
1,026 (68.3%)

800 (29.8%)
1,664 (70.2%)
<0.001 (4)

4,490 (27.4%)
9,828 (57.4%)
2,047 (15.2%)

3,574 (28.8%)
7,502 (58.4%)
1,314 (12.7%)

330 (25.0%)
862 (51.8%)
319 (23.2%)

586 (22.5%)
1,464 (56.3%)
414 (21.2%)

10,216 (52.8%)
5,541 (42.5%)
565 (4.0%)
43 (0.7%)

8,109 (57.1%)
3,859 (38.6%)
392 (3.8%)
30 (0.5%)

798 (41.6%)
630 (51.9%)
72 (4.0%)
11 (2.4%)

1,309 (41.2%)
1,052 (53.7%)
101 (4.9%)
2 (0.2%)

<0.001 (8)

<0.001 (6)
7,668 (38.0%)
5,044 (30.4%)
3,124 (25.2%)

6,225 (42.0%)
3,696 (29.8%)
2,121 (22.6%)
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518 (28.1%)
545 (32.2%)
370 (32.7%)

925 (27.0%)
803 (32.0%)
633 (32.0%)

Unknown
Insurance coverage
Private insurance only
Any Medicaid insurance
Other insuranced
Uninsured at any time of survey
Break in insurance coverage
Currently insured and has never had
a break
Currently insured but had a break at
some point
Currently uninsured but has had
insurance in the past
Currently uninsured and has never
had insurance

529 (6.3%)

348 (5.5%)

78 (7.0%)

103 (9.1%)
<0.001 (6)

8,803 (44.4%)
5,706 (44.6%)
1,356 (7.7%)
500 (3.3%)

7,131 (48.4%)
3,999 (41.9%)
982 (7.5%)
278 (2.3%)

605 (34.8%)
648 (50.4%)
146 (8.3%)
112 (6.5%)

1,067 (33.1%)
1,059 (52.6%)
228 (8.4%)
110 (5.9%)
<0.001 (6)

14,744 (89.4%)

11,350 (90.8%)

1,258 (84.4%)

2,136 (85.9%)

1,093 (7.4%)

750 (6.9%)

134 (9.2%)

209 (8.5%)

349 (2.3%)

214 (1.9%)

54 (3.0%)

81 (3.9%)

144 (0.9%)

61 (0.4%)

56 (3.3%)

27 (1.7%)

p-values were calculated using Rao-Scott chi-square tests to account for complex survey design
with zero providers (n=287, 0.9% of total study population) were excluded from this chi-square test as all 287 children, by definition, had not started any vaccine
series
c Not yes represents no, do not know, never heard of WIC, and refused to answer responses
d Other insurance may include: CHIP, IHS, military, or other, alone or in combination with private insurance
CHIP, Children’s Health Insurance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children
a

b Children
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Sample characteristics and bivariate associations
Table 1 shows the count and weighted distribution of sociodemographic factors for the total study sample
as well as by vaccination pattern. Among children who completed the combined 7-vaccine series (pattern 1), a
lower proportion (8.9%) had moved across state lines since birth compared to children missing ≥1 vaccine series
(pattern 2: 14.6%) and children missing ≥1 vaccine dose(s) (pattern 3: 15.6%). A greater proportion of children
UTD were non-Hispanic White (49.2%), accessed care at private facilities (59.7%), and were privately insured
(48.4%) compared to children missing ≥1 series (43.0%, 45.0% and 34.8%, respectively) and children missing
≥1 dose(s) from multi-dose series (40.8%, 49.5% and 33.1%, respectively; Table 1).
Characterization of children undervaccinated
Vaccination coverage by dose was calculated to understand when children fall behind on multi-dose
vaccine series. Notably, between the third and fourth doses of DTaP, PCV, and Hib (depending on manufacturing
brand), vaccination coverage dropped from 93.3% to 83.3%, 91.6% to 82.5%, and 90.9% to 81.6%, respectively.
Approximately 9-10% of children needed only one final dose of DTaP, PCV, or Hib to be caught up. Next,
timeliness of series initiation was evaluated across vaccine series. MMR and VAR showed the lowest proportion
of children starting on-time (MMR: 82.4%, VAR: 81.0%), suggesting nearly one out of five children experienced
delays to MMR and VAR receipt. For multi-dose vaccines, DTaP, PCV, Hib, HepB, and IPV, a greater proportion
of children (83.8%-88.3%) were starting on-time, which is important to ensure on-time series completion (Table
2).
The number of remaining doses needed to complete the combined 7-vaccine series was calculated, and
8.2% of the entire population needed only one additional dose to be considered UTD; these children represented
nearly half of children who initiated all series but did not complete all multi-dose series (44.6%). Children needing
between 2-5 doses consisted of 8.5% of all U.S. children. Among children who started but did not complete all
multi-dose series, the majority of children needed fewer than five doses to complete the combined 7-vaccine
series (1 dose remaining: 44.6%, 2-5 doses remaining: 30.6%) and very few children (n=127) needed more than
six doses to be UTD (Table 3).

Table 2. Characterization of undervaccination among U.S. children ages 19-35 months
Vaccine series
HepB
IPV
n (%)
n (%)

DTaP
n (%)

PCV
n (%)

Hib*
n (%)

15,796
(96.7%)

15,723
(96.3%)

15,767
(96.4%)

15,890
(98.0%)

Dose 2

15,629
(95.4%)

15,516
(94.5%)

15,517
(94.3%)

Dose 3

15,381
(93.3%)

15,184
(91.6%)

Dose 4

13,911
(83.3%)

Up-to-date coverage
by dosea
Dose 1

MMR
n (%)

VAR
n (%)

15,733
(96.4%)

15,168
(91.8%)

15,030
(90.9%)

15,539
(95.2%)

15,550
(94.7%)

—

—

15,044
(90.9%)

15,087
(91.3%)

15,243
(92.3%)

—

—

13,935
(82.5%)

13,784
(81.6%)

—

—

—

—

1,470
(10.0%)

1,249
(9.1%)

1,733
(see notes*)

452
(3.9%)

307
(2.4%)

—

—

14,781
(88.3%)

14,477
(86.5%)

14,574
(86.9%)

13,681
(83.8%)

14,619
(87.2%)

13,911
(82.4%)

13,601
(81.0%)

Children missing only the
final dose
On-time series initiationb
Dose 1

* Brand type factored into these calculations; however, series completion reported for all 4 doses of Hib represents overall
vaccination coverage for Hib, and includes n=3,264 children up-to-date with 3 doses of PRP-OMP vaccine type and n=10,520
children were up-to-date with 4 doses of PRP-T vaccine type. The weighted percentage represents overall vaccination coverage
for all Hib brand types. Among children who needed 4-doses of Hib (PRP-T vaccine type), n=1,260, 9.3% of total population,
were missing the final dose (i.e., were only up-to-date on 3 out of 4 doses needed for that series). Among children who initiated
the 3-dose Hib series (PRP-OMP vaccine type), n=473, 3.4% of total population, were missing the final dose (i.e., only up-todate on 2 out of 3 recommended doses).
a Up-to-date vaccination coverage among total study population. Excludes any vaccinations received after the household
interview date, as NIS interviews can serve as a reminder prompt for parents to complete vaccine series if a child was not upto-date at time of survey.
b Vaccines considered late one month after the dose was recommended by ACIP. The following age in days parameters were
used: HepB, 32 d; DTaP, 93 d; PCV, 93 d; Hib, 93 d; IPV, 93 d; MMR, 489 d; VAR, 489 d
—, not applicable
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Table 3. Remaining doses needed to complete the combined 7-vaccine series and close the coverage gap among
undervaccinated U.S. children ages 19-35 months
Undervaccination Pattern
Number of remaining
doses needed to complete
the combined 7-vaccine
seriesa,b
1 dose
2-5 doses
6-10 doses
11-15 doses
16-18 doses
All doses (19 doses)d

Total study sample
N = 16,365
n
(column %)
1,242 (8.2%)
1,184 (8.5%)
293 (2.3%)
206 (1.7%)
263 (2.2%)
314 (1.1%)

Missing ≥ 1
vaccine series
n=1,511
n
(column %)
94 (5.0%)
468 (32.0%)
187 (16.7%)
185 (12.9%)
263 (21.9%)
314 (11.5%)

All series initiated, but did not
complete all multi-dose series
n=2,464c
n
(column %)
1,148 (44.6%)
716 (30.6%)
106 (3.5%)
21 (2.3%)
0 (0%)
—

19 doses was considered up-to-date with the combined 7-vaccine series and included: four doses of diphtheria, tetanus, and
acellular pertussis (DTaP), three doses of poliovirus (IPV), one dose of MMR, three doses of hepatitis B (HepB), three doses of
Haemophilus influenzae type b (Hib), one dose of varicella (VAR), and four doses of pneumococcal conjugate vaccine (PCV). Hib
manufacturing brand was not factored into this calculation only. Note, this approach overestimated the number of children upto-date and underestimated the number of children who started a 4-dose Hib series and needed only one remaining final dose.
Among the n=12,863 children up-to-date with 19 doses under the 3+ Hib doses assumption, n=473 were actually missing the
final dose of 4-dose Hib (i.e., were missing 1 dose needed to complete the combined 7-vaccine series and would have needed a
total of 20 doses to be considered up-to-date). To calculate the weighted percentage among of the total study population, the
more lenient 3+ Hib doses of any brand type assumption was applied.
b Calculations reflect antigen containing shots, so receipt of one combination injection could represent multiple doses.
c Because a more lenient definition of up-to-date for Hib was applied for this calculation (3+ doses of any brand type), this
column does not sum to n=2,464 children classified in the all series initiated, but not completed pattern.
d By definition, children in the all seven series initiated, but did not complete multi-dose series pattern had received at least seven
doses.
—, not applicable
a

Factors associated with specific vaccination patterns
Risk factors for initiating but not completing all multi-dose series (i.e., pattern 3: missing ≥1 dose(s)) are
shown in Table 4. When examining a sub-cohort of children who had either completed the combined 7-vaccine
series (pattern 1) or had started but failed to complete multi-dose vaccine series (pattern 3), the odds of starting
but not completing multi-dose series were greater for non-Hispanic Black children (versus non-Hispanic White,
aOR: 1.35, 95% CI: 0.99-1.84), younger children surveyed at ages 19-23 months (ACIP recommends children be
UTD by age 19 months) compared to children ages 30-35 months who had additional time in the first two years
of life to catch up and complete final doses (aOR: 1.26, 95% CI: 0.98-1.61), and children who had moved across
state lines since birth (aOR: 1.66, 95% CI: 1.24-2.23). Living in lower income households (above poverty,
≤$75,000: aOR: 1.40, 95% CI: 1.00-1.95; below poverty: aOR: 1.45, 95% CI: 0.96-2.18), with multiple children
(two to three: aOR: 1.36, 95% CI: 1.07-1.73; four or more: aOR: 1.93, 95% CI: 1.38-2.70), and being uninsured
(uninsured at time of survey but had previously had health insurance: aOR: 1.67, 95% CI: 1.02-2.72; uninsured
since birth: aOR: 3.21, 95% CI: 1.56-6.62) were associated with increased likelihood of starting but not
completing all multi-dose series.
Our secondary analysis focused on the sub-cohort of children who were undervaccinated: either they had
not started all series (pattern 2), or had started all series but failed to complete multi-dose series (pattern 3).
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Overall, weaker associations were observed. After adjusting for sociodemographic differences, the odds of
initiating all series but not completing multi-dose series (pattern 3) were greater for children with multiple
providers (two: aOR: 1.78, 95% CI: 1.00-3.17; three or more: aOR: 6.33, 95% CI: 1.97-20.29). A greater number
of children in the household was a risk factor relative to pattern 2, and increased maternal education appeared to
be a protective factor against missing doses (pattern 3) and a risk factor for selective vaccination (pattern 2).
Geographic mobility was not associated with either undervaccination pattern (Table 4).
In supplemental analyses, the entire cohort was analyzed. Geographic mobility as well as multiple children
in the household, household income ≤$75,000 (above and below poverty), and breaks in insurance coverage were
all associated with lower odds of combined 7-vaccine series completion. Interestingly, having multiple
immunization providers increased the likelihood of completing the combined 7-vaccine series (two providers:
aOR: 1.40, 95% CI: 1.07-1.84; Table S3). One final comparison was made between pattern 2, missing ≥1 vaccine
series, versus pattern 1, completed the combined 7-vaccine series. Geographic mobility had a notable effect on
undervaccination due to not starting at least one vaccine series (aOR: 1.95, 95% CI: 1.38-2.75), similar to pattern
3 versus pattern 1, and lack of insurance coverage was strongly associated with missing ≥1 vaccine series as
compared to pattern 1 (aOR: 8.09, 95% CI: 3.66-17.91;Table S4).
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Table 4. Factors associated with starting and not completing multi-dose vaccine series compared to children who completed the combined 7-vaccine
series and compared to children who did not initiate at least one vaccine series, U.S. children ages 19-35 months

All series initiated, but did not
Complete all multi-dose series
n = 2,464 (17.3%)
versus
Completed the combined 7-vaccine
series
n = 12,390 (72.7%)
Sociodemographic factors
Race and ethnicity
White alone, non-Hispanic
Black alone, non-Hispanic
All other races alone and multiple races, nonHispanic
Any race, Hispanic
Child’s age at time of survey interview
19-23 months
24-29 months
30-35 months
Census region
Northeast
South
West
Midwest
Geographic mobility
Has moved across state lines since birth
Has not moved across state lines since birth
Vaccine provider facility type
All private facilities
All public facilities
All hospital facilities

Odds Ratio
(95% CI)
Unadjusted

Odds Ratio
(95% CI)
Adjusteda

All series initiated, but did not
Complete all multi-dose series
n = 2,464 (17.3%)
versus
Missing ≥ 1 vaccine series
n = 1,511 (9.9%)
Odds Ratio
(95% CI)
Unadjusted

Odds Ratio
(95% CI)
Adjusteda

Referent
1.75 (1.34-2.29)**

Referent
1.35 (0.99-1.84)

Referent
1.26 (0.86-1.84)

Referent
1.17 (0.77-1.80)

1.09 (0.85-1.39)
1.41 (1.09-1.83)

0.90 (0.68-1.18)
0.90 (0.67-1.20)

0.88 (0.56-1.37)
1.12 (0.76-1.66)

0.85 (0.54-1.33)
1.01 (0.64-1.58)

1.26 (0.99-1.59)**
0.88 (0.70-1.12)*
Referent

1.26 (0.98-1.61)
0.87 (0.68-1.11)
Referent

0.85 (0.60-1.21)
0.81 (0.56-1.16)
Referent

0.76 (0.52-1.13)
0.77 (0.53-1.11)
Referent

0.84 (0.67-1.05)
Referent
1.08 (0.79-1.47)
0.78 (0.65-0.94)*

0.95 (0.74-1.20)
Referent
1.18 (0.86-1.62)
0.81 (0.66-0.99)*

0.80 (0.57-1.11)
Referent
0.81 (0.51-1.29)
0.69 (0.52-0.93)

0.91 (0.62-1.34)
Referent
0.95 (0.60-1.52)
0.79 (0.56-1.11)

1.88 (1.45-2.44)**
Referent

1.66 (1.24-2.23)**
Referent

1.08 (0.77-1.52)
Referent

1.00 (0.70-1.43)
Referent

Referent
1.88 (1.41-2.51)*
1.24 (0.92-1.67)

Referent
1.35 (0.98-1.87)
1.24 (0.90-1.71)

Referent
0.99 (0.62-1.58)
0.55 (0.37-0.83)**

Referent
1.00 (0.60-1.67)
0.61 (0.40-0.94)*

All military/other facilities
Mixed facility types
Missing
Number of vaccine providersb
One
Two
Three or more
Maternal education
<12 years
12 years
>12 years
College graduate
Child ever received WIC benefits
Yes
Not yesc
Child’s birth order
Firstborn
Not firstborn
Number of children <18 years of age in the
house
One
Two or three
Four or more
Home ownership
Home was owned or being bought
Home was rented
Other arrangement
Did not know or refused to answer
Poverty status
Above poverty, ≥$75,000
Above poverty, ≤$75,000
Below poverty
Unknown
Insurance coverage

1.58 (0.86-2.91)
1.47 (1.13-1.92)
N/A

1.24 (0.65-2.35)
1.35 (1.01-1.81)*
N/A

0.85 (0.39-1.84)
1.15 (0.67-1.96)
N/A

0.82 (0.38-1.75)
0.70 (0.37-1.35)
N/A

Referent
0.87 (0.67-1.14)
1.46 (0.87-2.47)

Referent
0.85 (0.65-1.12)
1.12 (0.64-1.96)

Referent
1.56 (1.04-2.33)
6.20 (2.26-17.00)**

Referent
1.78 (1.00-3.17)
6.33 (1.97-20.29)**

2.33 (1.68-3.24)**
1.64 (1.27-2.10)
1.34 (1.06-1.68)
Referent

1.41 (0.91-2.17)
1.17 (0.88-1.55)
1.03 (0.79-1.33)
Referent

0.86 (0.54-1.37)
0.86 (0.59-1.27)
0.69 (0.47-1.01)
Referent

1.07 (0.57-2.01)
0.84 (0.54-1.32)
0.65 (0.42-1.00)
Referent

1.55 (1.28-1.89)**
Referent

0.84 (0.61-1.14)
Referent

1.11 (0.83-1.49)
Referent

0.94 (0.64-1.39)
Referent

0.65 (0.53-0.80)**
Referent

N/A
N/A

0.92 (0.66-1.27)
Referent

N/A
N/A

Referent
1.23 (0.98-1.56)
2.13 (1.56-2.91)**

Referent
1.36 (1.07-1.73)
1.93 (1.38-2.70)

Referent
1.21 (0.81-1.81)
1.02 (0.64-1.62)

Referent
1.30 (0.84-2.01)
1.24 (0.75-2.04)

Referent
1.93 (1.59-2.35)**
1.81 (1.22-2.67)
N/A

Referent
1.40 (1.08-1.83)*
1.39 (0.88-2.20)
N/A

Referent
1.05 (0.77-1.42)
1.23 (0.67-2.23)
N/A

Referent
0.95 (0.68-1.34)
1.85 (0.89-3.87)
N/A

Referent
1.67 (1.32-2.11)
2.20 (1.70-2.85)**
N/A

Referent
1.40 (1.00-1.95)*
1.45 (0.96-2.18)
N/A

Referent
1.03 (0.70-1.52)
1.02 (0.70-1.50)
N/A

Referent
1.19 (0.78-1.80)
1.14 (0.64-2.02)
N/A
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Private insurance only
Any Medicaid insurance
Other insuranced
Uninsured at any time
Break in insurance coverage
Currently insured and has never had a break
Currently insured but had a break at some
point
Currently uninsured but has had insurance in
the past
Currently uninsured and has never had
insurance

Referent
1.84 (1.49-2.27)
1.65 (1.24-2.02)
3.76 (2.51-5.63)**

N/A
N/A
N/A
N/A

Referent
1.10 (0.78-1.54)
1.07 (0.69-1.67)
0.96 (0.58-1.58)

N/A
N/A
N/A
N/A

Referent

Referent

Referent

Referent

1.30 (0.95-1.77)*

1.08 (0.77-1.50)

0.91 (0.58-1.42)

0.78 (0.49-1.25)

2.24 (1.43-3.51)

1.67 (1.02-2.72)*

1.27 (0.70-2.31)

1.01 (0.52-1.97)

4.20 (2.09-8.40)**

3.21 (1.56-6.62)**

0.49 (0.24-0.99)*

0.42 (0.17-1.08)

a Missing

data were excluded from adjusted models. For the pattern 3, all series initiated but not completed, versus pattern 1, completed the combined 7-vaccine series,
model, n=14,356 observations were used. To compare pattern 3 versus pattern 2, at least one series missing, n=3,500 observations were used. Poverty status had n=529
children missing data, home ownership had n=43 children missing data, and n=287 children with zero vaccine providers were set to missing.
b Children with zero vaccine providers (n = 287, 0.9% of total study population) were excluded as these children, by definition, were classified as missing at least one
vaccine series and no comparison across vaccination patterns were possible.
c Not yes represents no, do not know, never heard of WIC, and refused to answer responses
d Other insurance may include: CHIP, IHS, military, or other, alone or in combination with private insurance
CHIP, Children’s Health Insurance Plan; IHS, Indian Health Service; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children
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Discussion
Consistent with what has been previously reported in the literature, our findings showed coverage for
multi-dose vaccine series (specifically, DTaP, PCV, and Hib) remain persistently lower than single-dose series
(MMR and VAR).17, 23 Multi-dose series non-completion is an important driver of low combined 7-vaccine series
completion rates (72.7%). A noteworthy proportion of U.S. children (8.2%) needed only one additional vaccine
dose to complete the combined 7-vaccine series. If the children who had initiated all series but were missing only
one outstanding dose (n=1,148) had received that final dose and completed the combined 7-vaccine series, the
U.S. would have met the target 80% coverage goal in 2019.
Assuring multi-dose series completion and final dose receipt is modifiable risk.13, 35-39 Before being
licensed, vaccines undergo rigorous research and development to optimize vaccine effectiveness and specific
dosing schedules, explaining why some vaccines are single-dose series and others are 3-4 dose series.48 Vaccine
schedule adherence is critical for optimal protection. In our analysis of three vaccination patterns, geographic
mobility, number of immunization providers, number of children in household, household income, and breaks to
insurance coverage were notable factors associated with specific vaccination patterns. Our findings suggest that
despite the implementation of the federal Vaccines for Children (VFC) program designed to eliminate financial
barriers by providing free immunizations, other barriers to vaccination persist.54 To address high levels of
undervaccination, it is imperative to understand the underlying reasons as interventions designed to address
structural access barriers or series non-completion fundamentally differ from interventions targeting parental
vaccine hesitancy. The findings from this study highlight risk factors for undervaccination due to multi-dose series
non-completion and add to the current understanding of other structural or non-hesitancy barriers to vaccination.
Interventions designed to increase vaccine uptake need to be barrier and context specific. Strategies to
increase rates of completion of multi-dose vaccine series could include more widespread adoption of reminderrecall systems, re-thinking how immunization services are delivered to children (i.e., developing protocols for
vaccine receipt in “non-traditional” settings, in addition to clinic-based services), and supporting immunization
records coordination through investment in staffing as well as state immunization information systems (IIS) and
user-centered electronic health record (EHR) interoperability to ensure data quality.55 Because structural and other
barriers are broad, the prevalence of specific barriers and their effects on undervaccination need to be understood.
Examples may include system-level barriers and facilitators such as variation in state vaccination policies such
as day-care immunization requirements (e.g., many children who are not UTD at ages 19-35 months are caught
up by kindergarten due to school enrollment requirements), clustering of non-medical exemptions (e.g., if a child
had an adverse reaction to a vaccine dose that changed a parent’s attitude toward series completion and nonmedical exemptions were easy to obtain), inadequate surveillance data collection, or support services for enrolling
children in public health insurance programs.56-62 Our findings specifically underscore the importance of assuring
acquisition and maintenance of continuous health insurance coverage for vulnerable children. Provider-level
barriers may include immunization provider shortages, appointment availability outside of business hours, or lack
of IIS-EHR compatibility and immunization record scattering.63, 64 This analysis highlights an opportunity to
better support children seeking a medical home after moving across state lines and to counteract record scattering,
when children have multiple immunization providers, by investing in medical data systems. Individual-level
barriers may include transportation challenges, fragmentation of care, managing the well-child medical care of
multiple children, challenges affording health services, and health insurance coverage. Because structural and
other non-hesitancy barriers to vaccination may be geographically clustered, targeted interventions are needed to
assure equitable access to vaccines. Understanding factors associated with specific undervaccination patterns can
help clinical and public health partners better support children more likely to not complete vaccine series. This
study adds to a limited body or research describing children who face non-hesitancy or other barriers to
vaccination.50, 53, 65
Strengths and Limitations
To our knowledge, no previous studies have comprehensively described U.S. children who initiate but do
not complete all multi-dose vaccine series in the combined 7-vaccine series. Assuring on-time series completion
in the first two years of life is of utmost importance as children are most at risk for severe outcomes from VPDs

at young ages. Multi-dose series non-completion is a notable driver of persistently low vaccination rates. The
findings from this study work toward describing this public health problem, and can be used to ensure future
efforts center immunization equity to optimally protect children at both the individual and population level.
Importantly, NIS-Child data from the 2019 survey year were analyzed because they were the most recent available
data prior to the COVID-19 pandemic. Disruptions to care from March 2020 to present have resulted in higher
levels of undervaccination, due to both structural or other barriers as well as increased vaccine hesitancy, and
highlight the importance and urgency of supporting vaccine series completion.66, 67
This study had several limitations. First, child age at time of NIS household interview ranged from 19-35
months, so older children had a greater opportunity to catch up and complete vaccine series as compared to
children surveyed at age 19 months (combined 7-vaccine series coverage at 19-23 months: 68.4%, 24-29 months:
75.1%, and 30-35 months: 74.2%; Table S3). Because of this, age at time of survey was controlled for in
multivariable models. The emphasis of this study was on series completion; however, future studies should
explore structural and other non-hesitancy barriers to timely vaccine receipt, with a greater emphasis on schedule
adherence to decrease VPD risk. Second, NIS data user guides caution misclassification of Hib series completion
for three versus four dose series. With the sole exception of the remaining dose calculations in Table 3, which
were more lenient, our vaccination coverage estimates accounted for Hib brand type (i.e., three or four dose
series). However, if manufacturer was not specified in data collection, NIS-Child assumes the child initiated the
more widely used four dose series and children with only three doses would be classified as not UTD. This is a
documented limitation of the dataset. Misclassification of the outcome variable was possible if any one of the
seven vaccine series was misclassified in the source dataset (e.g., due to invalid doses). However, in our approach
CDC’s UTD flags were used for the creation of the outcome variable, and coverage estimates were consistent
with the reporting in the 2019 NIS data user guide. NIS-Child is considered the gold standard for assessing U.S.
vaccination coverage at the national and state level and is weighted to be representative of all U.S. children. Third,
while NIS-Child documentation and analytic recommendations are to subset on provider-verified data, it is
possible that coverage could be slightly overestimated due to selection bias. This is another noted limitation of
the data source.
Lastly, because the objective of this study was to describe the children who start but did not complete all
multi-dose series, explanatory variables measuring broader structural barriers and possible disruptions to care, as
well as factors stabilizing access, were included in the analysis. It is possible that variance was underestimated in
regression analysis due to correlation among covariates. However, multicollinearity was evaluated and highly
correlated variables were dropped from the final models. Non-hesitancy barriers to vaccination are broad and
complicate describing the scope of structural and other barriers. While the goal of this study was to characterize
this public health problem by explaining predictors of series non-completion, we cannot conclude that our
outcome of interest, pattern 3: all series initiated, but did not complete all multi-dose series, does not include any
vaccine hesitant parents (e.g., due to adverse reactions on previous doses or changing knowledge, attitudes, and
behaviors toward vaccination between birth and age 24 months). Future work should validate patterns suggestive
of structural, non-hesitancy barriers to vaccination.
Conclusions
Risk factors for starting but failing to complete multi-dose vaccine series included lower socioeconomic
status, moving across state lines since birth, having multiple children in the household, and being uninsured.
Understanding factors associated with starting and not completing multi-dose vaccine series can help us to better
support children who, despite VFC, face other barriers to vaccination. Series completion is an evidence-based
strategy to decrease VPD risk within and across communities, assure children have optimal protection, and
increase vaccination coverage to meet public health goals.35, 38, 48
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ABBREVIATIONS
ACIP
CI
DTaP
HepB
HepA
Hib
HPSA
IPV
MMR
MUA/P
NIS
NVAC
PCV
Ro
RV
UTD
VAR
VFC
VPD
WIC

Advisory Committee on Immunization Practices
Confidence interval
Diphtheria, tetanus, acellular pertussis
Hepatitis B
Hepatitis A
Haemophilus influenzae type b
Health Professions Shortage Areas
Inactivated poliovirus vaccine
Measles, mumps, and rubella
Medically Underserved Area/Populations
National Immunization Survey
National Vaccine Advisory Committee
Pneumococcal conjugate vaccine
Basic reproductive number
Rotavirus
Up-to-date
Varicella
Vaccines for Children
Vaccine Preventable Diseases
Special Supplemental Nutrition Program for Women, Infants, and Children
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SUPPLEMENTAL TABLES AND FIGURES
Table S1. U.S. Advisory Committee on Immunization Practices (ACIP) recommended early childhood immunization schedule, 2019

Birth
Vaccine series
Hepatitis B, (HepB)*
Diphtheria-tetanus-acellular
pertussis (DTaP)*
Haemophilus Influenzae type b (Hib)*
Pneumococcal conjugate (PCV)*
Poliovirus (IPV)*
Measles-mumps-rubella (MMR)*
Varicella (VAR)*
Rotavirus (RV)
Hepatitis A (HepA)
Influenza

1st dose

Depending on brand.
* Included in the combined 7-vaccine series
a

1
month

2
months

4
months

6
months

2nd dose

9
months

12
months

15
months

18
months

3rd dose

1st dose

2nd dose

3rd dose

1st dose
1st dose
1st dose

2nd dose
2nd dose
2nd dose

3rd dosea
3rd dose

1st dose

2nd dose

3rd dosea

4th dose
3rd or 4th dose
4th dose
rd
3 dose
1st dose
1st dose
2-dose series (6 mo. interval)
Annual vaccination 1-2 doses

23
Months

Table S2. Vaccination coverage at the time of household interview among U.S. children ages 19-35 months, NIS-Child 2019
Vaccination patterna

Vaccine series

Combined 7-vaccine series completion
Vaccines in combined 7-vaccine series:
Hepatitis B, (HepB) 3 doses
Diphtheria-tetanus-acellular pertussis (DTaP), 4 doses
Haemophilus influenzae type b (Hib), 3 or 4 dosesb
Pneumococcal conjugate (PCV), 4 doses
Poliovirus (IPV), 3 doses
Measles-mumps-rubella (MMR), 1 dose
Varicella (VAR), 1 dose
Other routine childhood vaccines:
Hepatitis A (HepA), 2 doses
Rotavirus (RV), 3 doses
Influenza, 2 doses

Total study
sample
N = 16,365

Completed the
combined 7-vaccine
series
n = 12,390 (72.7%)

Missing ≥ 1
vaccine series
n = 1,511 (9.9%)

All series initiated,
but did not complete
all multi-dose series
n = 2,464 (17.3%)

n
(column %)
12,390 (72.7%)

n
(column %)
12,390 (100%)

n
(column %)
0 (0%)

n
(column %)
0 (0%)

15,087 (91.3%)
13,911 (83.3%)
13,784 (81.6%)
13,935 (82.5%)
15,243 (92.3%)
15,168 (91.8%)
14,973 (90.9%)

12,390 (100%)
12,390 (100%)
12,390 (100%)
12,390 (100%)
12,390 (100%)
12,390 (100%)
12,390 (100%)

564 (40.2%)
279 (14.8%)
289 (17.2%)
266 (14.3%)
591 (38.7%)
314 (17.2%)
175 (11.5%)

2,133 (84.3%)
1,242 (52.7%)
1,005 (41.6%)
1,279 (48.0%)
2,262 (90.7%)
2,464 (100%)
2,464 (100%)

10,596 (63.1%)
12,945 (76.0%)
10,047 (57.2%)

9,358 (75.7%)
11,092 (88.4%)
8,743 (67.7%)

132 (6.9%)
412 (30.1%)
190 (10.5%)

1,106 (42.7%)
1,441 (50.4%)
1,114 (39.7%)

a Vaccination

coverage by pattern reports the coverage (column %) within each subclassification. By definition, children in patterns 2 and 3 were not up-to-date for the
combined 7-vaccine series.
b Depending on manufacturing brand
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Table S3. Up-to-date combined 7-vaccine series coverage by sociodemographic characteristics and factors associated with combined 7-vaccine series completion
compared to all undervaccinated U.S. children ages 19-35 months, NIS-Child 2019

Total study population
combined 7-vaccine
coverage
N = 16,365
Sociodemographic factors
n
(row %)

Completed the combined 7-vaccine series
n = 12,290 (72.7%)
versus
All undervaccinated children
(i.e., not up-to-date with combined 7-vaccine series)
n = 3,975
Odds Ratio
Odds Ratio
(95% CI)
(95% CI)
Unadjusted
Adjusted

Child’s sex
Female
Male
Race and ethnicity
White alone, non-Hispanic
Black alone, non-Hispanic
All other races alone and multiple races, non-Hispanic
Any race, Hispanic
Child’s age at time of survey interview
19-23 months
24-29 months
30-35 months
Census region
Northeast
South
West
Midwest
Geographic mobility
Has moved across state lines since birth
Has not moved across state lines since birth
Vaccine provider facility type
All private facilities
All public facilities

5,904 (72.6%)
6,486 (72.8%)

Referent
0.89 (0.70-1.14)

N/A
N/A

7,623 (75.9%)
794 (66.1%)
1,541 (73.3%)
2,432 (70.0%)

Referent
0.62 (0.50-0.77)**
0.87 (0.69-1.11)
0.74 (0.60-0.92)

Referent
0.77 (0.59-1.00)*
1.04 (0.80-1.34)
1.06 (0.81-1.38)

3,673 (68.4%)
3,878 (75.1%)
4,839 (74.2%)

0.75 (0.62-0.92)**
1.05 (0.86-1.28)*

0.73 (0.59-0.90)**
0.81 (0.61-1.07)

Referent

Referent

2156 (74.5%)
4,974 (72.7%)
2,656 (69.7%)
2,604 (74.9%)

1.09 (0.91-1.32)

1.04 (0.85-1.27)

Referent
0.87 (0.67-1.12)
1.12 (0.95-1.31)

Referent
0.77 (0.57-1.02)
0.67 (0.53-0.86)

1,129 (61.0%)
11,261 (74.1%)

0.55 (0.44-0.68)**

0.58 (0.45-0.74)**

Referent

Referent

7,000 (77.5%)
1,193 (64.6%)

Referent
0.53 (0.41-0.69)*

Referent
0.77 (0.57-1.02)
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All hospital facilities
All military/other facilities
Mixed facility types
Missing
Number of vaccine providersa
One
Two
Three or more
Maternal education
<12 years
12 years
>12 years
College graduate
Child ever received WIC benefits
Yes
Not yesb
Child’s birth order
Firstborn
Not firstborn
Number of children <18 years of age in the house
One
Two or three
Four or more
Home ownership
Home was owned or being bought
Home was rented
Other arrangement
Did not know or refused to answer
Poverty status
Above poverty, ≥$75,000
Above poverty, ≤$75,000
Below poverty
Unknown
Insurance coverage

2,084 (68.8%)
312 (67.3%)
1,801 (70.9%)
287

0.64 (0.51-0.80)
0.60 (0.37-0.96)
0.71 (0.55-0.91)
N/A

0.67 (0.53-0.86)**
0.79 (0.47-1.33)
0.68 (0.50-0.93)*
N/A

10,170 (72.7%)
1,999 (77.8%)
221 (72.2%)

Referent
1.31 (1.05-1.65)
0.98 (0.60-1.60)

Referent
1.40 (1.07-1.84)*
1.33 (0.77-2.32)

915 (61.3%)
1,774 (69.3%)
3,059 (71.8%)
6,642 (79.6%)

0.41 (0.31-0.54)**
0.58 (0.47-0.72)
0.65 (0.53-0.80)

0.74 (0.51-1.07)
0.81 (0.63-1.04)
0.84 (0.66-1.06)

Referent

Referent

4,508 (68.7%)
7,882 (76.6%)

0.67 (0.57-0.79)**

1.16 (0.91-1.47)

Referent

Referent

5,042 (77.5%)
7,348 (69.9%)

1.49 (1.25-1.77)**

N/A

Referent

N/A

3,574 (76.6%)
7,502 (74.0%)
1,314 (60.8%)

Referent
0.87 (0.71-1.07)**
0.47 (0.36-0.62)**

Referent
0.81 (0.65-1.02)
0.56 (0.41-0.75)**

8,109 (78.6%)
3,859 (66.0%)
392 (68.6%)
30 (58.4%)

Referent
0.53 (0.45-0.62)**
0.59 (0.42-0.85)
N/A

Referent
0.71 (0.57-0.89)**
0.86 (0.56-1.33)

6,225 (80.4%)
3,696 (71.3%)
2,121 (65.2%)
348 (63.8%)

Referent
0.61 (0.50-0.74)
0.46 (0.37-0.57)**

Referent
0.77 (0.59-0.99)*
0.71 (0.51-1.00)
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Private insurance only
Any Medicaid insurance
Other insurance c
Uninsured at any time
Break in insurance coverage
Currently insured and has never had a break
Currently insured but had a break at some point
Currently uninsured but has had insurance in the past
Currently uninsured and has never had insurance
Missing

7,131 (79.3%)
3,999 (68.3%)
982 (70.4%)
278 (50.0%)

Referent
0.56 (0.47-0.68)
0.62 (0.48-0.80)
0.26 (0.19-0.37)**

N/A

11,350 (74.0%)
750 (68.0%)
214 (58.0%)
61 (33.1%)
35

Referent
0.74 (0.57-0.97)**
0.48 (0.33-0.72)
0.17 (0.10-0.30)**
N/A

Referent
0.86 (0.65-1.16)
0.61 (0.39-0.96)*
0.22 (0.12-0.41)**

a Children

N/A
N/A
N/A

with zero vaccine providers (n = 287, 0.9%) were excluded as there were 0 children with zero providers in the UTD comparison group
Not yes represents no, do not know, never heard of WIC, and refused to answer responses
c Other insurance may include: CHIP, IHS, military, or other, alone or in combination with private insurance
CHIP, Children’s Health Insurance Plan; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children
b
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Table S4. Factors associated with missing at least one vaccine series compared up-to-date U.S. children ages 19-35 months
Missing ≥1 vaccine series
n = 1,511 (9.9%)
versus
Completed the combined 7-vaccine series
n = 12,390 (72.7%)
Sociodemographic factors
Race and ethnicity
White alone, non-Hispanic
Black alone, non-Hispanic
All other races alone and multiple races, nonHispanic
Any race, Hispanic
Child’s age at time of survey interview
19-23 months
24-29 months
30-35 months
Census region
Northeast
South
West
Midwest
Geographic mobility
Has moved across state lines since birth
Has not moved across state lines since birth
Vaccine provider facility type
All private facilities
All public facilities
All hospital facilities
All military/other facilities
Mixed facility types
Missing

Odds Ratio
(95% CI)
Unadjusted

Odds Ratio
(95% CI)
Adjusted

Referent
1.39 (1.02-1.91)

Referent
1.10 (0.75-1.63)

1.24 (0.82-1.88)
1.26 (0.90-1.75)

1.05 (0.67-1.63)
0.98 (0.61-1.59)

1.48 (1.10-1.99)**
1.10 (0.81-1.49)
Referent

1.61 (1.14-2.26)**
1.08 (0.76-1.55)
Referent

1.06 (0.80-1.41)
Referent
1.32 (0.90-1.96)
1.13 (0.88-1.45)

1.03 (0.74-1.44)
Referent
1.33 (0.86-2.06)
1.00 (0.74-1.34)

1.75 (1.30-2.34)**
Referent

1.95 (1.38-2.75)**
Referent

Referent
1.90 (1.25-2.88)
2.24 (1.64-3.05)**
1.86 (1.05-3.31)
1.28 (0.78-2.09)
N/A

Referent
1.27 (0.80-2.01)
2.02 (1.44-2.83)**
1.25 (0.64-2.45)
1.73 (0.94-3.20)
N/A

26

Number of vaccine providersa
One
Two
Three or more
Maternal education
<12 years
12 years
>12 years
College graduate
Child ever received WIC benefits
Yes
Not yesb
Child’s birth order
Firstborn
Not firstborn
Number of children <18 years of age in the
house
One
Two or three
Four or more
Home ownership
Home was owned or being bought
Home was rented
Other arrangement
Did not know or refused to answer
Poverty status
Above poverty, ≥$75,000
Above poverty, ≤$75,000
Below poverty
Unknown
Insurance coverage
Private insurance only
Any Medicaid insurance
Other insurance c

Referent
0.56 (0.40-0.78)
0.24 (0.09-0.60)*

Referent
0.50 (0.29-0.84)**
0.18 (0.06-0.52)**

2.72 (1.84-4.02)**
1.90 (1.38-2.61)
1.93 (1.39-2.68)
Referent

1.26 (0.69-2.28)
1.37 (0.91-2.06)
1.58 (1.07-2.34)*
Referent

1.40 (1.09-1.79)**
Referent

0.92 (0.66-1.28)
Referent

0.71 (0.54-0.94)*
Referent

N/A
N/A

Referent
1.02 (0.72-1.46)**
2.09 (1.39-3.15)**

Referent
1.06 (0.70-1.61)
1.58 (0.94-2.64)

Referent
1.85 (1.43-2.39)*
1.47 (0.84-2.60)
N/A

Referent
1.46 (1.04-2.06)*
0.72 (0.34-1.55)
N/A

Referent
1.62 (1.16-2.25)
2.16 (1.57-3.00)**
N/A

Referent
1.14 (0.82-1.58)
1.31 (0.77-2.22)
N/A

Referent
1.67 (1.25-2.23)
1.54 (1.04-2.27)

N/A
N/A
N/A

27

Uninsured at any time
Break in insurance coverage
Currently insured and has never had a break
Currently insured but had a break at some
point
Currently uninsured but has had insurance in
the past
Currently uninsured and has never had
insurance

3.92 (2.51-6.13)**

N/A

Referent

Referent

1.43 (0.97-2.11)*

1.33 (0.87-2.04)

1.76 (1.01-3.07)

1.50 (0.76-2.95)

8.56 (4.65-15.76)**

8.09 (3.66-17.91)**

a Children

with zero vaccine providers (n = 287, 0.9%) were excluded as there were 0 children with zero providers in the UTD referent group
Not yes represents no, do not know, never heard of WIC, and refused to answer responses
c Other insurance may include: CHIP, IHS, military, or other, alone or in combination with private insurance
CHIP, Children’s Health Insurance Plan; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children
b
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